Evidence map›Paper›PMID 36568647›Full record

ArticleSensors and actuators. B, Chemical2021

Recent advances in sensitive surface-enhanced Raman scattering-based lateral flow assay platforms for point-of-care diagnostics of infectious diseases.

Kihyun Kim, Leila Kashefi-Kheyrabadi, Younju Joung, Kyeongnyeon Kim, Hajun Dang, Sachin Ganpat Chavan, Min-Ho Lee, Jaebum Choo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sensors and actuators. B, Chemical, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Lyophilizing SERS biosensors to enable translation into an easy-to-use assay.Analytical methods : advancing methods and applications · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kihyun KimDepartment of Chemistry, Chung-Ang University, Seoul, 06974, South Korea.
Leila Kashefi-KheyrabadiSchool of Integrative Engineering, Chung-Ang University, Seoul, 06974, South Korea.
Younju JoungDepartment of Chemistry, Chung-Ang University, Seoul, 06974, South Korea.
Kyeongnyeon KimDepartment of Chemistry, Chung-Ang University, Seoul, 06974, South Korea.
Hajun DangDepartment of Chemistry, Chung-Ang University, Seoul, 06974, South Korea.
Sachin Ganpat ChavanSchool of Integrative Engineering, Chung-Ang University, Seoul, 06974, South Korea.
Min-Ho LeeSchool of Integrative Engineering, Chung-Ang University, Seoul, 06974, South Korea.
Jaebum ChooDepartment of Chemistry, Chung-Ang University, Seoul, 06974, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review reports the recent advances in surface-enhanced Raman scattering (SERS)-based lateral flow assay (LFA) platforms for the diagnosis of infectious diseases. As observed through the recent infection outbreaks of COVID-19 worldwide, a timely diagnosis of the disease is critical for preventing the spread of a disease and to ensure epidemic preparedness. In this regard, an innovative point-of-care diagnostic method is essential. Recently, SERS-based assay platforms have received increasing attention in medical communities owing to their high sensitivity and multiplex detection capability. In contrast, LFAs provide a user-friendly and easily accessible sensing platform. Thus, the combination of LFAs with a SERS detection system provides a new diagnostic modality for accurate and rapid diagnoses of infectious diseases. In this context, we briefly discuss the recent application of LFA platforms for the POC diagnosis of SARS-CoV-2. Thereafter, we focus on the recent advances in SERS-based LFA platforms for the early diagnosis of infectious diseases and their applicability for the rapid diagnosis of SARS-CoV-2. Finally, the key issues that need to be addressed to accelerate the clinical translation of SERS-based LFA platforms from the research laboratory to the bedside are discussed.

Indexed as

AuNPs, gold nanoparticlesBA, bacillary angiomatosisCRISPR, Clustered Regularly Interspaced Short Palindromic RepeatcrRNAs, CRISPR RNAsHIV, human immunodeficiency virusIFA, indirect immunofluorescence assayIgG, immunoglobulin GIgM, immunoglobulin MInfectious diseaseIn vitro diagnostics (IVD)KSHV, Kaposi’s sarcoma herpes virusLateral flow assay (LFA)LFA, lateral flow assayNC, nitrocelluloseNS1, nonstructural protein 1POC, point-of-carePoint-of-care (POC)PRV, pseudorabies virusRT-PCR, real-time polymerase chain reactionSARS-CoV-2SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2SEB, staphylococcal enterotoxinSERS, surface-enhanced Raman scatteringSi-AuNPs, silica-encapsulated AuNPsSurface-enhanced Raman scattering (SERS)

Identifiers

PMID36568647
PMCPMC9759493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.